The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Sarcoma and Rare Cancers 2023 | Ripretinib in UK patients with advanced GIST
Robin Jones, MBBS, MRCP, MD, The Royal Marsden Hospital, London, UK, comments on findings from the extended access program which investigated the efficacy and safety profile of ripretinib in UK patients with advanced gastrointestinal stromal tumors (GIST). The study revealed a favorable efficacy and safety profile, which Prof. Jones hopes will encourage the eventual reimbursement of UK patients with advanced GIST following use of this tyrosine-kinase inhibitor (TKI). This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
